Current concepts and review of efalizumab in the treatment of psoriasis.
Leonardi
Craig L
CL
Department of Dermatology, St. Louis University School of Medicine, 1755 S Grand, St. Louis, MO 63104, USA. leonardi@centralderm.com
D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D007279:Injections, Subcutaneous; D008297:Male; D020714:Maximum Tolerated Dose; D011379:Prognosis; D011565:Psoriasis / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology*; D018570:Risk Assessment; D012720:Severity of Illness Index; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C472181:efalizumab